Androgen Deprivation Therapy Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Androgen Deprivation Therapy Market Report is Segmented by Therapeutics Class (Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, and Antiandrogens), Route of Administration (Injectable and Oral), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The Report Offers the Value (in USD) for the Above Segments.

Androgen Deprivation Therapy Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Androgen Deprivation Therapy Market Size

Androgen Deprivation Therapy Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 6.45 Billion
Market Size (2030) USD 8.56 Billion
CAGR (2025 - 2030) 5.80 %
Fastest Growing Market North America
Largest Market Asia-Pacific
Market Concentration Medium

Major Players

Androgen Deprivation Therapy Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Androgen Deprivation Therapy Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Androgen Deprivation Therapy Market Analysis

The Androgen Deprivation Therapy Market size is estimated at USD 6.45 billion in 2025, and is expected to reach USD 8.56 billion by 2030, at a CAGR of 5.8% during the forecast period (2025-2030).

The key factors propelling the market growth are the rising burden of prostate cancer, increasing research and development activities, advancements in treatment technology for effective treatment of prostate cancer, rising product approvals, and strategic initiatives adopted by key market players.

The growing burden of prostate cancer is expected to increase demand for effective treatment with androgen deprivation therapy, thereby boosting the market growth. For instance, according to the Canadian Cancer Society Report 2024, prostate cancer is set to account for one in five new cancer cases in Canadian males, with an estimated 27,900 new diagnoses expected in 2024. Thus, the high incidence of prostate cancer is expected to contribute to the segment growth over the forecast period.

Strategies such as partnerships, distribution agreements, mergers, and acquisitions adopted by key market players are expected to boost market growth. For instance, in May 2022, Myovant Sciences and Accord Healthcare Ltd entered an exclusive license agreement for Accord to commercialize Relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name ORGOVYX (Relugolix, 120 mg) in the European Economic Area, the United Kingdom, Switzerland, and Turkey. Such partnerships will expand the accessibility of ORGOVYX across geographies, thereby leading to lucrative market growth.

Furthermore, achieving milestones in the drug development cycle will also fuel market growth. For instance, in May 2022, Bayer reported that the United States Food and Drug Administration (FDA) accepted a supplemental New Drug Application (NDA) and granted Priority Review for the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (HSBC). Similarly, in March 2023, the European Commission approved Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Therefore, owing to the factors above, the market is expected to grow significantly during the study period. However, limited reimbursement policies and increasing side effects are expected to hinder the market growth during the study period.

Androgen Deprivation Therapy Industry Overview

The androgen deprivation therapy market is moderately competitive. The strategies such as mergers and acquisitions and partnerships adopted by the key players will boost the market. The major players in the market studied are Johnson & Johnson, AstraZeneca, Bayer AG, Astellas Pharma, and Tolmar Pharmaceuticals Inc.

Androgen Deprivation Therapy Market Leaders

  1. Johnson and Johnson

  2. Astrazeneca

  3. Bayer AG

  4. Astellas Pharma Inc.

  5. Tolmar Pharmaceuticals, Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Androgen Deprivation Therapy Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Androgen Deprivation Therapy Market News

  • July 2024: Ubix Therapeutics Inc. entered an exclusive licensing agreement with Yuhan Corporation. The deal focuses on developing and commercializing UBX-103, a preclinical androgen receptor (AR) degrader program. Yuhan will have exclusive, worldwide rights for the preclinical and clinical development and commercialization of UBX-103. Ubix will receive an upfront payment of more than USD 3.6 million (approximately KRW 5 billion).
  • March 2023: OliX Pharmaceuticals Inc. announced that it received approval from the Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1 clinical trial of OLX72021. It is a treatment for androgenic alopecia, also known as male-pattern baldness. OLX72021 suppresses the hormone activity that causes androgenic alopecia by reducing the expression of the androgen receptor.

Androgen Deprivation Therapy Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Prostrate Cancer
    • 4.2.2 Rising Research and Development Activities
  • 4.3 Market Restraints
    • 4.3.1 Poor Reimbursement and Increasing Side Effects
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - in USD)

  • 5.1 By Therapeutic Class
    • 5.1.1 Luteinizing Hormone-releasing Hormone (LHRH) agonists
    • 5.1.2 Antiandrogens
  • 5.2 By Route of Administration
    • 5.2.1 Injectable
    • 5.2.2 Oral
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Johnson and Johnson
    • 6.1.2 Astrazeneca
    • 6.1.3 Bayer AG
    • 6.1.4 Astellas Pharma Inc.
    • 6.1.5 AbbVie Inc.
    • 6.1.6 Tolmar Pharmaceuticals Inc.
    • 6.1.7 Verity Pharmaceuticals Inc.
    • 6.1.8 Foresee Pharmaceuticals Co. Ltd
    • 6.1.9 Myovant Sciences GmbH
    • 6.1.10 Ferring BV
    • 6.1.11 Viatris
    • 6.1.12 Bristol-Myers Squibb Company
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Androgen Deprivation Therapy Industry Segmentation

As per the scope of the report, androgen deprivation therapy is hormone therapy for prostate cancer in males by suppressing excess androgen. Androgen is a sex hormone produced in the testes and adrenalin glands in the form of testosterone and dihydrotestosterone.

The androgen deprivation therapy market is segmented by therapeutic class, route of administration, and geography. By therapeutic class, the market is segmented as luteinizing hormone-releasing hormone (LHRH) agonists and antiandrogens. By route of administration, the market is segmented as injectable and oral. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.

By Therapeutic Class Luteinizing Hormone-releasing Hormone (LHRH) agonists
Antiandrogens
By Route of Administration Injectable
Oral
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Androgen Deprivation Therapy Market Research FAQs

How big is the Androgen Deprivation Therapy Market?

The Androgen Deprivation Therapy Market size is expected to reach USD 6.45 billion in 2025 and grow at a CAGR of 5.80% to reach USD 8.56 billion by 2030.

What is the current Androgen Deprivation Therapy Market size?

In 2025, the Androgen Deprivation Therapy Market size is expected to reach USD 6.45 billion.

Who are the key players in Androgen Deprivation Therapy Market?

Johnson and Johnson, Astrazeneca, Bayer AG, Astellas Pharma Inc. and Tolmar Pharmaceuticals, Inc. are the major companies operating in the Androgen Deprivation Therapy Market.

Which is the fastest growing region in Androgen Deprivation Therapy Market?

North America is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Androgen Deprivation Therapy Market?

In 2025, the Asia-Pacific accounts for the largest market share in Androgen Deprivation Therapy Market.

What years does this Androgen Deprivation Therapy Market cover, and what was the market size in 2024?

In 2024, the Androgen Deprivation Therapy Market size was estimated at USD 6.08 billion. The report covers the Androgen Deprivation Therapy Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Androgen Deprivation Therapy Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Global Androgen Deprivation Therapy Industry Report

Statistics for the 2025 Androgen Deprivation Therapy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Androgen Deprivation Therapy analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.